Cancer Policy Trump administration announces “major crackdown” on healthcare fraud February 27, 2026Vol.52 No.08By Claire Marie Porter
Cancer Policy FDA issues draft guidance on accelerating development of individualized therapies for ultra-rare diseases February 27, 2026Vol.52 No.08
Cancer Policy At Friends meeting, Pazdur, Woodcock lament FDA’s failure to protect the agency staff from political interference, warn of “lasting implications” February 20, 2026Vol.52 No.07By Jacquelyn Cobb and Claire Marie Porter
Cancer Policy Bayer agrees to $7.25B settlement over lawsuits alleging Roundup weedkiller caused cancer February 20, 2026Vol.52 No.07By Sara Willa Ernst
Cancer Policy Super Bowl ad by Hims & Hers features GRAIL’s Galleri MCD test February 13, 2026Vol.52 No.06By Jacquelyn Cobb and Sara Willa Ernst
Cancer Policy FDA approves labeling changes to menopausal hormone therapy products February 13, 2026Vol.52 No.06By Claire Marie Porter
Cancer Policy HHS withdraws 340B drug rebate pilot program February 13, 2026Vol.52 No.06By Sara Willa Ernst
Cancer Policy NIH’s Bhattacharya acknowledges absence of causal link between vaccines and autism February 06, 2026Vol.52 No.05By Sara Willa Ernst
Cancer Policy “Basic Experimental Studies Involving Humans” no longer classified as clinical trials at NIH in an effort to reduce administrative burden February 06, 2026Vol.52 No.05By Jacquelyn Cobb
